RFPs: Independent Medical Education Grants to optimize ER+ Metastatic Breast Cancer Treatment

Pfizer Inc. and Arvinas are collaborating to provide grant support for continuing professional education in metastatic Breast Cancer (mBC).

.

Area of Interest
  • This competitive grant program seeks to support independent medical education activities focused on the evolving treatment landscape for patients with ER+/HER2- mBC.
  • Applicants are encouraged to identify and address the educational needs of healthcare professionals related to novel treatments in the evolving clinical landscape of ER+/HER2- mBC. Proposed educational activities should focus on increasing the understanding of emerging mechanisms of action (MOA) of novel agents, practice-changing clinical updates for mBC and how to incorporate them safely and effectively for appropriate patients – particularly in the post-CDK4/6 inhibitor(s) setting.
  • Projects that will be considered for grant support will focus on one or more of the following:
    • Increasing understanding of emerging and novel therapeutic agents in the evolving treatment landscape of ER+/HER2- mBC
    • Exploring the current unmet needs in ER+/HER2- mBC, including the relevance and applicability of biomarker testing
    • Increasing understanding of differentiated MOA of emerging therapies including proteolysis targeting chimera estrogen receptor (PROTAC ER) degraders from that of other endocrine therapies (e.g., SERDs)
    • Increasing understanding of the latest clinical data updates relevant to the treatment of patients with ESR1 mutated ER+/HER2- mBC
Funding Information
  • Individual projects requesting up to $175,000 will be considered although smaller, focused projects with lower budgets are preferred.
  • The estimated total available budget related to this RFP is $730,000.
Duration
  • Anticipated approximate Project Start and End Dates: July 2025 – June 2026 (15-month maximum execution timeline, i.e., from contract execution to provision of final outcomes).
Target Audience and Geographic Scope
  • The intended learner audience should include medical oncologists and other healthcare professionals involved in breast cancer patient care.
  • The geographic scope of this RFP is global with the United States as the primary priority.

Eligibility:
  • The following types of organizations may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
  • Please note:
    • Only organizations are eligible to receive grants, not individuals or medical practice groups.
    • If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
    • The project/program lead must be an employee or contractor of the requesting organization.
    • Requesting organization must be legally able to receive award funding directly from Pfizer Inc.
    • For projects offering continuing education credit, the requesting organization must be accredited.

…………………………………………………………………………………………

At Funding Square, we help African entrepreneurs and organizations access funding through three expert services:

.

  1. Grant Research Service – Get 50 tailored grant opportunities handpicked for your business or nonprofit, saving you time and effort.
  2. Grant Proposal Writing – We craft compelling, funder-friendly proposals that grab attention and increase your chances of success.
  3. Fundraising Business Plan – A powerful, funding-ready business plan designed to attract grants, loans, and investors.

Let’s turn your funding goals into reality!

.

Contact us today by sending us an email at hello@fundingsquare.org

Search
Recent posts
Tags